Log in | Register

Using multiple 'omics strategies for novel therapies in sepsis

James A. Russell| Peter Spronk| Keith R. Walley
Editorial
Volume 44, Issue 4 / April , 2018

Pages 509 - 511

No abstract available.

References

  1. Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:801–810
    • View reference on publisher's website
    • View reference on PubMed
  2. Opal SM, Laterre PF, Francois B et al (2013) Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309:1154–1162
    • View reference on publisher's website
    • View reference on PubMed
  3. Seymour CW, Gesten F, Prescott HC et al (2017) Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 376:2235–2244
    • View reference on publisher's website
    • View reference on PubMed
  4. Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45:486–552
    • View reference on publisher's website
    • View reference on PubMed
  5. Kumar A (2010) Early antimicrobial therapy in severe sepsis and septic shock. Curr Infect Dis Rep 12:336–344
    • View reference on publisher's website
    • View reference on PubMed
  6. Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369:840–851
    • View reference on publisher's website
    • View reference on PubMed
  7. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW (1988) Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 318:727–732
    • View reference on publisher's website
    • View reference on PubMed
  8. Petersen L, Sorensen TI, Andersen PK (2010) A shared frailty model for case-cohort samples: parent and offspring relations in an adoption study. Stat Med 29:924–931
    • View reference on publisher's website
    • View reference on PubMed
  9. Walley KR, Thain KR, Russell JA et al (2014) PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med 6:258
    • View reference on publisher's website
  10. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA (2012) Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 367:1891–1900
    • View reference on publisher's website
    • View reference on PubMed
  11. Seidah NG, Abifadel M, Prost S, Boileau C, Prat A (2017) The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin/kexin 9. Pharmacol Rev 69:33–52
    • View reference on publisher's website
    • View reference on PubMed
  12. Stein EA, Mellis S, Yancopoulos GD et al (2012) Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 366:1108–1118
    • View reference on publisher's website
    • View reference on PubMed
  13. Abifadel M, Rabes JP, Devillers M et al (2009) Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 30:520–529
    • View reference on publisher's website
    • View reference on PubMed
  14. Stower H (2011) Human genetics: pleiotropic mutations. Nat Rev Genet 13:5
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement